H.R. 4132 · 119th Congress · Health
Prescription Information Modernization Act of 2025
- IntroducedJun 25, 2025 Done
- CommitteeReferred to Energy and Commerce Current stage
- House floorNot yet Not reached yet
- Senate floorNot yet Not reached yet
- Chambers agreeNot yet Not reached yet
- PresidentNot yet Not reached yet
Full text
No CRS summary yet · 367 wordsH.R. 4132 · Introduced in House · Jun 25, 2025
This Act may be cited as the Prescription Information Modernization Act of 2025 .
(a) In general. Section 502(f) of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 352(f) ) is amended by adding at the end the following: Required prescribing information for drugs subject to section 503(b)(1) may be made available solely by electronic means provided that the labeling complies with all applicable requirements of law, that the manufacturer affords prescribers and dispensers the opportunity to elect to also continue to receive all such information in paper form, or to request paper labeling on an as-needed basis, and after such request, and that the manufacturer promptly provides the requested information without additional cost. .
(b) Rulemaking. (1) In general Not later than 1 year after the date of the enactment of this Act, the Secretary of Health and Human Services shall issue final regulations to— (A) implement the amendment made by subsection (a); and (B) provide instructions on how health care professionals can receive paper copies of prescribing information directly from the manufacturer or distributor if desired. (2) Economic impacts The Secretary of Health and Human Services shall design the regulations required by paragraph (1) so as to minimize the adverse economic impacts of such regulations on prescribers and dispensers.
(c) Public workshop. Not later than 2 years after the date of the enactment of this Act, the Secretary of Health and Human Services, acting through the Commissioner of Food and Drugs, shall hold a public workshop with relevant stakeholders to discuss how to continue to optimize the format, accessibility, and usability of prescribing information.
(d) Effective date. The amendment made by subsection (a) shall apply with respect to drugs introduced or delivered for introduction into interstate commerce on or after the sooner of— (1) the date that is 2 years after the date of the enactment of this Act; or (2) the effective date of the final regulations promulgated to implement such amendment.
(e) Definition. In this section, the term drug has the meaning given to such term in section 201 of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 321 ).
Shown here because the text is under 500 words. Open on Congress.gov
Who lobbies on it
8 organizations, more than 96% of House bills · 32 filings · Q2 2025–Q3 2026These 8 organizations’ PACs gave $64.5K to 10 of the 17 members sponsoring or cosponsoring H.R. 4132 in the 2025–26 election cycle.
One square per quarter since introduction, oldest left. Filled = named it that quarter.
-
Cencora, Inc.
6 of 6 quarters
“Essential Medicines Strategic Stockpile Department of Defense Essential Medicines Strategic Stockpile Prescription Information Modernization Act (H.R.4132/S.2027) Mitigation of Drug Shortages Pharmaceutical supply chain resilience National Defense Authorization Act for Fiscal Year 2027 (NDAA - H.R.8800/S.4784) Supply…”
$2.1M lobbying spend in 2026 to date, all issuesQ3 2026 filing
-
Viatris Inc
6 of 6 quarters
“S. 891, the Bipartisan Health Care Act Part D Formulary Design and Generic Drug Tiering HR 4132 / S.2027 - Prescription Information Modernization Act Medicaid Generics Penalty Implementation of the Inflation Reduction Act Drug Shortages S. 2658, The Medication Affordability and Patent Integrity Act”
$1.3M lobbying spend in 2026 to date, all issuesQ3 2026 filing
-
Printing United Alliance
6 of 6 quarters
“Advocating for the Patients Right to Know Their Medication Act (HR 5133), which requires the information to be provided in printed form. Opposing the Pharmaceutical Information Modernization Act of 2025 (H.R. 4132/S. 2027), which would allow the FDA to finalize a proposed rule permitting drug manufacturers to send…”
$150K lobbying spend in 2026 to date, all issuesQ3 2026 filing
5 more organizations, every filingPROUpgrade
Organizations that named H.R. 4132 in a quarterly lobbying report. Covers organizations with a PAC on file; reports from organizations without one aren’t loaded yet. Spend is the organization’s total across all issues: reports don’t split spending by bill. “Gave to” means the organization’s PAC gave to the member’s campaign in the 2025–26 cycle, net of refunds; it doesn’t mean the money was about this bill. Organizations may lobby for, against, or to change a bill; filings don’t say which. Source: Senate lobbying disclosures (LD-2) from lda.gov; PAC gifts from FEC filings; quotes are word for word from the “specific lobbying issues” field; where a filing lists many bills, the quote starts where it names this one.
Actions
2 actions · newest first- Jun 25, 2025Referred to the House Committee on Energy and Commerce.
- Jun 25, 2025Introduced in House